JP4800924B2 - 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 - Google Patents

癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 Download PDF

Info

Publication number
JP4800924B2
JP4800924B2 JP2006504071A JP2006504071A JP4800924B2 JP 4800924 B2 JP4800924 B2 JP 4800924B2 JP 2006504071 A JP2006504071 A JP 2006504071A JP 2006504071 A JP2006504071 A JP 2006504071A JP 4800924 B2 JP4800924 B2 JP 4800924B2
Authority
JP
Japan
Prior art keywords
cancer
cells
pharmaceutical composition
virus
myxoma virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006504071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519789A (ja
Inventor
グラント マクファデン，
ジョン シー． ベル，
Original Assignee
ロバーツ リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロバーツ リサーチ インスティテュート filed Critical ロバーツ リサーチ インスティテュート
Publication of JP2006519789A publication Critical patent/JP2006519789A/ja
Application granted granted Critical
Publication of JP4800924B2 publication Critical patent/JP4800924B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2006504071A 2003-03-07 2004-03-08 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 Expired - Fee Related JP4800924B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45252103P 2003-03-07 2003-03-07
US60/452,521 2003-03-07
US45539303P 2003-03-18 2003-03-18
US60/455,393 2003-03-18
PCT/CA2004/000341 WO2004078206A1 (en) 2003-03-07 2004-03-08 Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011112835A Division JP2011157399A (ja) 2003-03-07 2011-05-19 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用

Publications (2)

Publication Number Publication Date
JP2006519789A JP2006519789A (ja) 2006-08-31
JP4800924B2 true JP4800924B2 (ja) 2011-10-26

Family

ID=32965588

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006504071A Expired - Fee Related JP4800924B2 (ja) 2003-03-07 2004-03-08 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用
JP2011112835A Withdrawn JP2011157399A (ja) 2003-03-07 2011-05-19 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011112835A Withdrawn JP2011157399A (ja) 2003-03-07 2011-05-19 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用

Country Status (11)

Country Link
US (2) US7582614B2 (enExample)
EP (1) EP1601376B1 (enExample)
JP (2) JP4800924B2 (enExample)
KR (1) KR101116858B1 (enExample)
AU (1) AU2004216928C1 (enExample)
CA (1) CA2517147C (enExample)
IL (1) IL170601A (enExample)
MX (1) MXPA05009526A (enExample)
NZ (1) NZ541951A (enExample)
RU (1) RU2362584C2 (enExample)
WO (1) WO2004078206A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011157399A (ja) * 2003-03-07 2011-08-18 Robarts Research Inst 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
NZ560840A (en) * 2005-03-07 2009-07-31 Robarts Res Inst Use of a combination of myxoma virus and rapamycin for therapeutic treatment
WO2007143538A2 (en) * 2006-06-01 2007-12-13 Robarts Research Institute Pike-a enhances infection by myxoma virus
KR20090014364A (ko) * 2006-06-01 2009-02-10 로바츠 리서치 인스티튜트 암 치료용 점액종 바이러스 변이종
DK2717887T3 (en) 2011-06-09 2018-04-09 Univ Florida Methods for treating or preventing graft-versus-host disease
CN109982709A (zh) * 2016-11-17 2019-07-05 Vcn生物科学有限公司 病毒载体在治疗视网膜母细胞瘤中的用途
CA3074901A1 (en) 2017-09-11 2019-03-14 Imba - Institut Fur Molekulare Biotechnologie Gmbh Tumor organoid model
WO2019177438A1 (ko) * 2018-03-16 2019-09-19 바이로큐어 주식회사 암 치료를 위한 레오바이러스 및 믹소마폭스 바이러스의 병용
RU2699754C1 (ru) * 2018-05-08 2019-09-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Флуоресцирующая клеточная линия глиомы и способ её получения
US12128099B2 (en) 2018-05-25 2024-10-29 Bioventures, Llc Myxoma virus compositions and methods of use
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020036341A1 (ko) * 2018-08-17 2020-02-20 바이로큐어 주식회사 암 치료를 위한 다람쥐폭스 바이러스 및 믹소마폭스 바이러스의 병용
WO2020051248A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
WO2020106880A1 (en) 2018-11-20 2020-05-28 Bioventures, Llc Cells for the production of viruses and methods of using the same
US11591616B1 (en) 2019-04-22 2023-02-28 Colorado State University Research Foundation Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
WO1997026904A1 (en) 1996-01-25 1997-07-31 Medical Research Council Treatment of non-neuronal cancer using hsv mutant
WO1999004026A2 (en) 1997-07-18 1999-01-28 Chiron Corporation Lentiviral vectors
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
CA2378567A1 (en) * 1999-07-12 2001-01-18 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
EP1601376B1 (en) * 2003-03-07 2012-05-30 Robarts Research Institute Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011157399A (ja) * 2003-03-07 2011-08-18 Robarts Research Inst 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用

Also Published As

Publication number Publication date
EP1601376B1 (en) 2012-05-30
RU2005131020A (ru) 2006-03-10
AU2004216928B2 (en) 2007-03-08
NZ541951A (en) 2008-03-28
US7582614B2 (en) 2009-09-01
WO2004078206A1 (en) 2004-09-16
MXPA05009526A (es) 2005-12-15
EP1601376A1 (en) 2005-12-07
JP2006519789A (ja) 2006-08-31
AU2004216928C1 (en) 2007-03-08
JP2011157399A (ja) 2011-08-18
US8227440B2 (en) 2012-07-24
AU2004216928A1 (en) 2004-09-16
US20090317362A1 (en) 2009-12-24
CA2517147A1 (en) 2004-09-16
CA2517147C (en) 2011-06-14
KR20050111349A (ko) 2005-11-24
US20060263333A1 (en) 2006-11-23
KR101116858B1 (ko) 2012-03-06
RU2362584C2 (ru) 2009-07-27
IL170601A (en) 2010-11-30
HK1081099A1 (en) 2006-05-12

Similar Documents

Publication Publication Date Title
US8227440B2 (en) Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection
JP5674210B2 (ja) 治療的処置のための粘液腫ウイルスとラパマイシンの組み合わせの使用
CN100379453C (zh) 粘液瘤病毒在治疗癌症和慢性病毒感染中的用途
HK1081099B (en) Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
HK1163175B (en) Use of a myxoma virus that does not express functional m135r for therapeutic treatment

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101021

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110519

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110804

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140812

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4800924

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees